Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Masao Omata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7977-1497; OpenAlex author ID A5034244372, A5087952042. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2011: 5 papers · 2012: 3 papers · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 14

  1. A Real-world Study on the Prognosis of Patients with Pancreatic Cancer: A Prospective Stationary Survey from 2007-2020. Last author DOI 10.2169/internalmedicine.6719-25↗
  2. Liquid biopsy of wash samples obtained via endoscopic ultrasound-guided fine-needle biopsy: Comparison with liquid biopsy of plasma in pancreatic cancer. Last author DOI 10.1002/dc.25306↗
  3. Detection of actionable mutations in cytological specimens obtained by endoscopic ultrasound-guided fine needle aspiration with rapid onsite evaluation in panc… Last author DOI 10.1016/j.anndiagpath.2022.152008↗
  4. Genomic profiling amplifies the utility of endoscopic ultrasound-guided fine needle biopsy by identifying clinically applicable druggable mutations in pancreat… Last author DOI 10.1016/j.anndiagpath.2022.152016↗
  5. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Co-author DOI 10.1093/carcin/bgu136↗
  6. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Co-author DOI 10.1158/0008-5472.can-12-1453↗
  7. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. Co-author DOI 10.1007/s00535-011-0482-y↗
  8. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Co-author DOI 10.1038/bjc.2012.183↗
  9. Incidental pancreatic cysts found by magnetic resonance imaging and their relationship with pancreatic cancer. Last author DOI 10.1097/mpa.0b013e31824f5970↗
  10. Specific increase in serum autotaxin activity in patients with pancreatic cancer. Co-author DOI 10.1016/j.clinbiochem.2011.03.128↗
  11. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Co-author DOI 10.1016/j.critrevonc.2010.05.007↗
  12. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2011.04.046↗
  13. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Co-author DOI 10.1159/000328767↗
  14. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci42754↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroshi Ohyama · 4 shared papers, 2022–2026 · strength 0.70
  2. Naoya Kato · 3 shared papers, 2022–2024 · strength 0.47
  3. Rintaro Mikata · 3 shared papers, 2022–2024 · strength 0.47
  4. Jun Kato · 1 shared paper, 2026 · strength 0.23
  5. Akinori Abe · 1 shared paper, 2026 · strength 0.23
  6. Hiroyuki Isayama · 9 shared papers, 2011–2014 · strength 0.22
  7. Kazuhiko Koike · 9 shared papers, 2011–2014 · strength 0.22
  8. Yousuke Nakai · 8 shared papers, 2011–2014 · strength 0.20
  9. Minoru Tada · 7 shared papers, 2011–2012 · strength 0.16
  10. Naoki Sasahira · 6 shared papers, 2011–2012 · strength 0.13
  11. Saburo Matsubara · 5 shared papers, 2011–2012 · strength 0.11
  12. Hirofumi Kogure · 5 shared papers, 2011–2012 · strength 0.11
  13. Koji Miyabayashi · 4 shared papers, 2011–2014 · strength 0.11
  14. Hideaki Ijichi · 4 shared papers, 2011–2014 · strength 0.11
  15. Dai Mohri · 4 shared papers, 2011–2013 · strength 0.10
  16. Keisuke Yamamoto · 3 shared papers, 2011–2014 · strength 0.08
  17. Takashi Sasaki · 3 shared papers, 2011–2012 · strength 0.07
  18. Harold L. Moses · 2 shared papers, 2011–2013 · strength 0.05
  19. Takashi Sasaki · 2 shared papers, 2011–2012 · strength 0.04
  20. Suguru Mizuno · 2 shared papers, 2011 · strength 0.04
  21. Kazumichi Kawakubo · 2 shared papers, 2011 · strength 0.04
  22. Norihiro Kokudo · 1 shared paper, 2014 · strength 0.03
  23. Motoyuki Otsuka · 1 shared paper, 2014 · strength 0.03
  24. Kuni Ohtomo · 1 shared paper, 2012 · strength 0.02
  25. Noriyoshi Fukushima · 1 shared paper, 2012 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.